We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
- Authors
Olsen, E; Duvic, M; Frankel, A; Kim, Y; Martin, A; Vonderheid, E; Jegasothy, B; Wood, G; Gordon, M; Heald, P; Oseroff, A; Pinter-Brown, L; Bowen, G; Kuzel, T; Fivenson, D; Foss, F; Glode, M; Molina, A; Knobler, E; Stewart, S; Cooper, K; Stevens, S; Craig, F; Reuben, J; Bacha, P; Nichols, J
- Abstract
The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 2, p376
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.2.376